About curis - CRIS
Curis, Inc. engages in the development and commercialization of drug candidates for the treatment of human cancers. Its pipeline includes CUDC-907, CA-4948, CA-170 and CA-327. The CUDC-907 pipeline is an orally available small molecule inhibitor of HDAC and PI3K enzymes. The CA-170 pipeline is an also an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints. The company was founded on February 14, 2000 and is headquartered in Lexington, MA.
CRIS At a Glance
Curis, Inc.
Building C
Lexington, Massachusetts 02421
| Phone | 1-617-503-6500 | Revenue | 10.91M | |
| Industry | Biotechnology | Net Income | -43,389,000.00 | |
| Sector | Health Technology | 2024 Sales Growth | 8.83% | |
| Fiscal Year-end | 12 / 2025 | Employees | 34 | |
| View SEC Filings |
CRIS Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 1.769 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.833 |
| Enterprise Value to Sales | 3.34 |
| Total Debt to Enterprise Value | 1.019 |
CRIS Efficiency
| Revenue/Employee | 320,823.529 |
| Income Per Employee | -1,276,147.059 |
| Receivables Turnover | 3.257 |
| Total Asset Turnover | 0.181 |
CRIS Liquidity
| Current Ratio | 1.387 |
| Quick Ratio | 1.387 |
| Cash Ratio | 1.051 |
CRIS Profitability
| Gross Margin | 97.241 |
| Operating Margin | -402.842 |
| Pretax Margin | -397.772 |
| Net Margin | -397.772 |
| Return on Assets | -72.167 |
| Return on Equity | -634.713 |
| Return on Total Capital | -139.38 |
| Return on Invested Capital | -100.901 |
CRIS Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 119.268 |
| Total Debt to Total Assets | 88.131 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 90.704 |